Purple Biotech Ltd. has taken a significant step towards expanding its financial capabilities by filing a pre-effective amendment to its registration statement with the Securities and Exchange Commission (SEC). This amendment allows the company to potentially sell up to $200 million in various securities, including American Depositary Shares (ADSs) and ordinary shares. This move is crucial for the company as it seeks to bolster its capital resources to support ongoing and future projects.
The filing, dated November 6, 2026, indicates that Purple Biotech is looking to enhance its operational capacity in the competitive pharmaceutical preparations industry. The company has previously sold ADSs under a sales agreement with H.C. Wainwright & Co., which may continue as it utilizes the new registration statement.
Background
Purple Biotech Ltd., classified under the SIC code 2834 for Pharmaceutical Preparations, operates primarily in the development of innovative therapies for cancer treatment. The company trades on the Nasdaq under the ticker symbol PPBT and is incorporated in Israel. Recent filings include a Form F-3/A on November 6, 2026, and a Form 6-K on October 5, 2026, among others.
What the Filing Says
The recent filing states, "This Pre-Effective Amendment No. 1... is being filed to include updated disclosures since the Registration Statement was originally filed on May 20, 2026." The amendment serves as a replacement registration statement under Rule 415(a)(6) of the Securities Act of 1933, allowing Purple Biotech to issue and sell securities that remain unsold from a previous registration statement.
Impact
This amendment may significantly impact investors and stakeholders in Purple Biotech, as it opens the door for substantial capital raising. The company has already sold approximately 691,806 ADSs for gross proceeds of about $2.3 million under the prior registration statement. With the new amendment, Purple Biotech can further engage in capital-raising activities, which could enhance its market position and operational capabilities.
What's Next
The filing does not specify what happens next, but it indicates that Purple Biotech will continue to pursue its capital-raising efforts through the newly amended registration statement. Investors and market participants will be watching closely for any additional updates or offerings that may arise from this development.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










